Thu, April 22, 2021
Wed, April 21, 2021
Tue, April 20, 2021
Mon, April 19, 2021
Fri, April 16, 2021
Thu, April 15, 2021

Matthew Harrison Maintained (VRTX) at Hold with Increased Target to $253 on, Apr 19th, 2021


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-253-on-apr-19th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Increased Target from $251 to $253 on, Apr 19th, 2021.

Matthew has made no other calls on VRTX in the last 4 months.



There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Geoffrey Porges of "SVB Leerink" Maintained at Hold with Decreased Target to $250 on, Tuesday, February 2nd, 2021


These are the ratings of the 5 analyists that currently disagree with Matthew


  • Brian Abrahams of "RBC Capital" Maintained at Buy and Held Target at $265 on, Friday, April 16th, 2021
  • Brian Skorney of "Baird" Upgraded from Hold to Buy and Increased Target to $252 on, Tuesday, February 23rd, 2021
  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $284 on, Tuesday, February 2nd, 2021
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $347 on, Tuesday, February 2nd, 2021
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $280 on, Tuesday, February 2nd, 2021

Publication Contributing Sources